We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 637

The competition and IP intersect
  • King & Wood Mallesons
  • Australia
  • February 13 2014

In a move which will be closely watched by the pharmaceutical industry, the ACCC has commenced proceedings against Pfizer alleging breaches of the

ACCC allegedly misled by Medicines Australia Code of Conduct
  • Russell Kennedy
  • Australia
  • August 25 2014

We previously reported that Medicines Australia submitted its 18th Edition of the Code of Conduct for approval by the ACCC. Subsequently, the Royal

ACCC v Pfizer some guidance to pharmaceutical companies on navigating competition risk
  • Herbert Smith Freehills LLP
  • Australia
  • March 3 2015

In brief The Federal Court of Australia has recently dismissed the ACCC’s case against pharmaceutical company Pfizer. The ACCC alleged that Pfizer had

Substantial market power now you have it, now you don’t. The decision in ACCC v Pfizer
  • Johnson Winter & Slattery
  • Australia
  • March 17 2015

The recent Federal Court decision in ACCC v Pfizer serves as strong reminder that market power is not static but must be assessed in the context of a

Australian Federal Court decides protecting your brand against generic pharmaceuticals is not a misuse of market power
  • Bird & Bird
  • Australia
  • March 18 2015

In a decision which will be welcomed by many pharmaceutical companies the Federal Court of Australia recently dismissed proceedings instituted by the

Hospital’s by-laws flatline on the competition table
  • King & Wood Mallesons
  • Australia
  • December 22 2014

The ACCC has launched proceedings in the Federal Court against Little Company of Mary Health Ltd and its subsidiary Calvary Health Care Riverina Ltd

ACCC issues report on private health insurance
  • Gilbert + Tobin
  • Australia
  • March 31 2013

The ACCC report on 'anti-competitive and other practices by health funds and providers in relation to private health insurance' has been tabled in

Harper Review dispenses important recommendations for the life sciences sector
  • DLA Piper LLP
  • Australia
  • May 6 2015

The long-awaited Harper Review final report was released on 31 March 2015. This update highlights key recommendations relevant to the life sciences

ACCC proposes to reauthorise collective negotiations by rural doctors
  • Corrs Chambers Westgarth
  • Australia
  • September 11 2013

On 28 August 2013, the ACCC issued a draft determination proposing to allow the Rural Doctors Association of Australia (RDAA) and its state

ACCC halts hospital merger
  • King & Wood Mallesons
  • Australia
  • June 18 2014

Healthscope is owned by private equity houses. It is Australia's largest private hospital owner, with 44 hospitals in Australia (and approximately 81